The Relationship of Serum Erythropoietin Level With Coronary Collateral Grade

Canadian Journal of Cardiology

Volumn 27, Issue 5, 2011, Pages 589-595

  Sahinarslan, Asife ^a   Yalcin, Ridvan ^a   Kocaman, Sinan Altan ^a   Ercin, Ugur ^a   Tanalp, Ali Cevat ^b   Topal, Salih ^a   Bukan, Neslihan ^a   Boyaci, Bulent ^a   Cengel, Atiye ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Yuzuncu Yil Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; ORAL ANTIDIABETIC AGENT; VASCULOTROPIN;

ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; OXYGEN SATURATION; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS;

ANGINA, STABLE; COLLATERAL CIRCULATION; CORONARY ANGIOGRAPHY; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 81255158796     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.04.001     Document Type: Article

References (36)

1. Sellke F.W., Wang S.Y., Stamler A., et al. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol 1996, 271:713-720.
2. Losordo D.W., Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines. Circulation 2004, 109:2487-2491.
3. Schaper W. Collateral circulation. Past and present. Basic Res Cardiol 2009, 104:5-21.
4. Schirmer S.H., van Nooijen F.C., Piek J.J., van Royen N. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart 2009, 95:191-197.
5. Schaper W., Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003, 23:1143-1151.
6. Sato T., Maekawa T., Watanabe S., Tsuji K., Nakahata T. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 2000, 106:263-270.
7. van der Meer P., Lipsic E., Henning R.H., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005, 46:125-133.
8. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007, 28:2208-2216.
9. Namiuchi S., Kagaya Y., Ohta J., et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005, 45:1406-1412.
10. Westenbrink B.D., Lipsic E., van der Meer P., et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007, 28:2018-2027.
11. Westenbrink B.D., Oeseburg H., Kleijn L., et al. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 2008, 22:265-274.
12. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002, 106:2973-2979.
13. Cohen M., Rentrop K.P. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation 1986, 75:325-334.
14. Habib G.B., Heibig J., Forman S.A., et al. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation 1991, 83:739-746.
15. Sherman J.A., Hall A., Malenka D.J., De Muinck E.D., Simons M. Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol 2006, 98:1194-1197.
16. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775-1780.
17. Bullard A.J., Yellon D.M. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther 2005, 19:333-336.
18. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003, 112:999-1007.
19. Cai Z., Manalo D.J., Wei G., et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003, 108:79-85.
20. Marrero M.B., Venema R.C., Ma H., Ling B.N., Eaton D.C. Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int 1998, 53:1259-1268.
21. Akimoto T., Kusano E., Inaba T., et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000, 58:269-282.
22. Ammarguellat F., Llovera M., Kelly P.A., Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2001, 284:1031-1038.
23. Akimoto T., Kusano E., Ito C., et al. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J Hypertens 2001, 19:193-202.
24. Gogusev J., Zhu D.L., Hérembert T., et al. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994, 199:977-983.
25. Amano K., Matsubara H., Iba O., et al. Enhancement of ischemia-induced angiogenesis by eNOS overexpression. Hypertension 2003, 41:156-162.
26. Unthank J.L., Nixon J.C., Dalsing M.C. Nitric oxide maintains dilation of immature and mature collaterals in rat hindlimb. J Vasc Res 1996, 33:471-479.
27. Wagner K.F., Katschinski D.M., Hasegawa J., et al. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 2001, 97:536-542.
28. Ruschitzka F.T., Wenger R.H., Stallmach T., et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A 2000, 97:11609-11613.
29. Toba H., Sawai N., Morishita M., et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009, 612:106-114.
30. Fleisch M., Billinger M., Eberli F.R., et al. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 1999, 100:1945-1950.
31. Sherman J.A., Hall A., Malenka D.J., De Muinck E.D., Simons M. Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol 2006, 98:1194-1197.
32. Briguori C., Testa U., Colombo A., et al. Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol 2006, 97:472-476.
33. Schultz A., Lavie L., Hochberg I., et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999, 100:547-552.
34. Steiner S., Schueller P.O., Schulze V., Strauer B.E. Occurrence of coronary collateral vessels in patients with sleep apnea and total coronary occlusion. Chest 2010, 137:516-520.
35. Werner G.S., Ferrari M., Betge S., et al. Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion. Circulation 2001, 104:2784-2790.
36. Hubacek J., Basran R.S., Shrive F.M., et al. Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention. Can J Cardiol 2009, 25:e42-e47.